Glassman Robert 4

What Happened

• Robert Glassman, a director of Pharvaris N.V. (PHVS), exercised options (derivative transactions) and sold shares on May 15, 2026. He exercised 5,333 option shares at an exercise price of $22.31 (cost $118,979). On the same day he sold a total of 10,000 shares in the open market: 5,333 shares for $159,091 (weighted price $29.83) and 4,667 shares for $139,155 (weighted price $29.82), for total sale proceeds of about $298,246. The Form 4 also reports a derivative disposal of 5,333 shares at $0 (see footnotes).

Key Details

• Transaction date: May 15, 2026; Form 4 filed May 19, 2026 (filed within the normal two-business-day window).
• Option exercise: 5,333 shares acquired at $22.31 per share (total cost $118,979). Footnote F3: the option was 100% vested as of April 11, 2025.
• Open-market sales: total 10,000 shares sold for combined proceeds ≈ $298,246. Reported weighted sale prices: ~ $29.82–$29.83 (individual sale prices ranged per F1/F2 from roughly $29.6550 up to $29.92 across the transactions).
• Shares owned after the transactions: not specified in the provided Form 4.
• Footnotes: F1/F2 note the weighted sale prices cover multiple trades and that the sold shares included shares acquired upon vesting of restricted stock units (RSUs) on various dates; the filer offers to provide detailed per-trade pricing on request.
• No 10b5-1 plan or late filing flag was disclosed on this Form 4.

Context

• The filing shows an option exercise paired with same-day open-market sales, which can reflect a cashless/exercise-and-sell pattern (some shares sold to cover exercise cost or taxes). Because the sales included shares from vested RSUs (per footnotes), not all sold shares necessarily came from the exercised options. This Form 4 is factual reporting of transactions; it does not state the insider's motive.